FIELD: chemistry.
SUBSTANCE: invention relates to genetic engineering, specifically to creation of fibroblast growth factor receptor (FGFR) muteins, and can be used in medicine. The polypeptide of the FGFR4 receptor extracellular domain (ECD) acidic region mutein is an FGFR4 ECD chimera or a FGFR4 long acid box version and has more acid residues in the D1-D2 linker region than the wild-type FGFR4 ECD. The muteins may include a point mutation that inhibits glycosylation. The mutein is used to treat a disease associated with one or more FGFR ligands, e.g., proliferative diseases, including various types of cancer, angiogenic disorders and macular degeneration.
EFFECT: invention enables to obtain an FGFR4 ECD acidic region mutein, having low capacity to bind with tissue, by increasing the number of amino acid residues within the D1-D2 linker region.
32 cl, 22 dwg, 11 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR, ALLOSTERIC BINDING INHIBITOR | 2010 |
|
RU2604805C2 |
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
| MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 | 2009 |
|
RU2546254C9 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME | 2013 |
|
RU2673943C2 |
| FGFR EXPRESSION AND SENSITIVITY TO FGFR INHIBITOR | 2016 |
|
RU2728674C2 |
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| BIGETEROARYL-SUBSTITUTED 1,4-BENZODIAZEPINES AND WAYS OF THEIR USE FOR CANCER TREATMENT | 2016 |
|
RU2747644C2 |
| ANTIBODIES AGAINST FGFR3 AND METHODS OF THEIR APPLICATION | 2010 |
|
RU2568066C2 |
